Interim Report

Period from January 2015 to June 2015

2015 SECOND QUARTER (Apr-Jun)

• Operating loss KSEK -3 863 (-2,404) 

• Loss per share SEK -0.41 (-0.35)

FIRST HALF YEAR 2015 (Jan-Jun)

• Operating loss KSEK -6,507 (-3,678)

• Loss per share SEK -0.69 (-0.54)

IMPORTANT EVENTS DURING THE PERIOD

• At the AGM in April, Mr Anders Wiklund and Prof. Emeritus Andris Kreicbergs were elected as new members to the Board. At the same time, Mr. Christer Sjögren and Mr. Ingvar Wiberger resigned from the Board.
  
  
• In April, Johan Inborr, CEO, subscribed for 160,000 warrants as authorized by the AGM as part of an adopted incentives scheme.

IMPORTANT EVENTS AFTER THE END OF THE PERIOD

•     Last patient exited the on-going phase IIb study in July. In total, 227 patients were randomized in to the study.

From the CEO

At Peptonic, the ongoing clinical study is the single most important activity at present. The last study subject entered the study in March and exited the same in July. This was in line with the study protocol and time schedule. In total, 227 subjects were randomized in to the study, which were a few short of the target of 240. In general, patient recruitment went very well, which indicates a great need for new and safe treatments for vaginal atrophy and that many women are suffering from the symptoms associated with vaginal atrophy. We are also pleased to note that the costs of the study did not exceed those of the original budget. Results from the study are expected to be announced in September.

Preparations for the next phase in the development of Vagitocin® - clinical phase 3 – are well underway. These include e.g. to secure commercial scale manufacturing of Vagitocin®, preparation for the advisory meetings with the regulatory authorities in the US and in Europe, and to plan for the discussions with potential partners with the aim of out-licensing the project.

Work is also underway to develop treatments based on oxytocin for additional indications. This work focuses on identifying and evaluating indications for which there are no good treatments today, the need for effective and safe medicines is pronounced, new or existing patents would provide good protection and that have an attractive market potential. We hope to be able to provide more information on these projects later this year.

In summary, we have an exciting autumn ahead of us. Stay tuned on the news flow to follow our progress.

Stockholm August 17th, 2015

Johan Inborr

CEO, Peptonic Medical AB

COMPANY BRIEF

Peptonic Medical AB is an innovative Swedish pharmaceutical company developing oxytocin based products e.g. for the treatment of menopausal symptoms, such as vaginal atrophy. Oxytocin has a long history of safe and effective medical use and offers an alternative to estrogen and estrogen-like acting compounds for menopausal and postmenopausal women. Peptonic Medical AB’s mission is to develop safe and effective drugs based on the known beneficial properties of oxytocin.

FINANCIAL INFORMATION

Net sales – Currently the company has no sales.

Costs – Costs for the second quarter were KSEK -3,863 (-2,404). Costs for the first half year were KSEK -6,507 (-3,678).

Result – Loss before tax for the second quarter was KSEK -3,863 (-2,404). Loss before tax for the first half year was KSEK -6,492 (-3,678).

Financial position and liquidity – Liquid assets were KSEK 13,558 (9,972) as of June 30, 2015. During the first half year the company raised KSEK 14,522 in a private placement.

Equity – The equity amounted to KSEK 48,940 (49,419) as of June 30, 2015. 85 (97) percent of which is shareholders funds.

Organization – The average number of employees during the period was 2 (1). At the end of the period the number of employees was 2 (1).

Share – Total numbers of shares in the company amounted to 9,441,960 (6,824,318), as of June 30, 2015.

Tags: